Solid Tumor
Conditions
Keywords
unspecified adult solid tumor, protocol specific
Brief summary
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving epidermal growth factor receptor inhibitors may help doctors understand the effect of epidermal growth factor receptor inhibitors on magnesium levels in the body. PURPOSE: This laboratory study is looking at the effect of epidermal growth factor receptor inhibitors on magnesium homeostasis in patients with cancer.
Detailed description
OBJECTIVES: * Determine the effects of EGFR inhibitors on magnesium homeostasis in patients with cancer. OUTLINE: This is a pilot study. Patients undergo blood and urine sample collection at baseline and at 2, 4, and 8 weeks during treatment. After finishing treatment, patients are followed periodically for up to 10 weeks.
Interventions
OTHERlaboratory biomarker analysis
laboratory biomarker analysis
Sponsors
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Vanderbilt-Ingram Cancer Center
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of malignancy * Planning to receive therapy with an inhibitor of the EGFR pathway (either on or off a clinical trial and may be monotherapy or combined with other therapies) * Normal serum magnesium level
Exclusion criteria
* Glomerular filtration rate ≥ 60 mL/min * No severe underlying renal dysfunction * Normal serum potassium and calcium level * No history of primary or secondary hyperparathyroidism PRIOR CONCURRENT THERAPY: * No prior EGFR pathway inhibitor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effects of EGFR inhibitors on magnesium homeostasis | 8 weeks |
Outcome results
None listed